PATH EX

company

About

PATH EX has developed a proprietary technology to selectively separate and capture bacteria and toxins from human blood.

  • 1 - 10

Details

Last Funding Type
Grant
Last Funding Money Raised
$225K
Industries
Health Diagnostics,Medical Device
Founded date
Jan 1, 2016
Number Of Employee
1 - 10
Operating Status
Active

PATH EX has developed a proprietary technology to selectively separate and capture bacteria and toxins from human blood, for the treatment of sepsis. Sepsis, a life-threatening condition that commonly presents itself as a blood-borne infection, is the number one cause of death in the ICU and is the largest cost on their healthcare system. PATH EX is taking a novel approach by capturing and removing intact bacteria from the blood rather than trying to kill the infection with broad spectrum antibiotics. The PATH EX device is effective regardless of bacteria type or drug resistance. The PATH EX technology has the potential to reduce diagnostic times, treatment costs, readmission rates, and sepsis related deaths.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$1.61M
PATH EX has raised a total of $1.61M in funding over 2 rounds. Their latest funding was raised on Oct 21, 2020 from a Non-Equity Assistant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 21, 2020 Non-Equity Assistant $100K 1 MassChallenge Texas Detail
Aug 16, 2018 Grant $1.29M 1 National Science Foundation Detail
Jul 10, 2017 Grant $225K 1 National Science Foundation Detail

Investors

Number of Lead Investors
Number of Investors
3
2
PATH EX is funded by 2 investors. MassChallenge Texas and National Science Foundation are the most recent investors.
Investor Name Lead Investor Funding Round
MassChallenge Texas Yes Non-Equity Assistant
National Science Foundation Yes Grant